These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

339 related items for PubMed ID: 29320568

  • 1. Gastrointestinal safety of etoricoxib in osteoarthritis and rheumatoid arthritis: A meta-analysis.
    Feng X, Tian M, Zhang W, Mei H.
    PLoS One; 2018; 13(1):e0190798. PubMed ID: 29320568
    [Abstract] [Full Text] [Related]

  • 2. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
    Cannon CP, Curtis SP, FitzGerald GA, Krum H, Kaur A, Bolognese JA, Reicin AS, Bombardier C, Weinblatt ME, van der Heijde D, Erdmann E, Laine L, MEDAL Steering Committee.
    Lancet; 2006 Nov 18; 368(9549):1771-81. PubMed ID: 17113426
    [Abstract] [Full Text] [Related]

  • 3. [By what means does the rheumatic patient with gastrointestinal risks fare best?].
    Einecke D.
    MMW Fortschr Med; 2007 Mar 08; 149(10):18. PubMed ID: 17408040
    [No Abstract] [Full Text] [Related]

  • 4. Etoricoxib: new drug. Avoid using cox-2 inhibitors for pain.
    Prescrire Int; 2007 Dec 08; 16(92):223-7. PubMed ID: 18084859
    [Abstract] [Full Text] [Related]

  • 5. Pooled analysis of thrombotic cardiovascular events in clinical trials of the COX-2 selective Inhibitor etoricoxib.
    Curtis SP, Ko AT, Bolognese JA, Cavanaugh PF, Reicin AS.
    Curr Med Res Opin; 2006 Dec 08; 22(12):2365-74. PubMed ID: 17265571
    [Abstract] [Full Text] [Related]

  • 6. Cardiovascular risk associated with celecoxib or etoricoxib: a meta-analysis of randomized controlled trials which adopted comparison with placebo or naproxen.
    De Vecchis R, Baldi C, Di Biase G, Ariano C, Cioppa C, Giasi A, Valente L, Cantatrione S.
    Minerva Cardioangiol; 2014 Dec 08; 62(6):437-48. PubMed ID: 25029569
    [Abstract] [Full Text] [Related]

  • 7. Use of gastroprotective agents and discontinuations due to dyspepsia with the selective cyclooxygenase-2 inhibitor etoricoxib compared with non-selective NSAIDs.
    Watson DJ, Bolognese JA, Yu C, Krupa D, Curtis S.
    Curr Med Res Opin; 2004 Dec 08; 20(12):1899-908. PubMed ID: 15701208
    [Abstract] [Full Text] [Related]

  • 8. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
    Laine L, Curtis SP, Cryer B, Kaur A, Cannon CP, MEDAL Steering Committee.
    Lancet; 2007 Feb 10; 369(9560):465-73. PubMed ID: 17292766
    [Abstract] [Full Text] [Related]

  • 9. Relative benefit-risk comparing diclofenac to other traditional non-steroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors in patients with osteoarthritis or rheumatoid arthritis: a network meta-analysis.
    van Walsem A, Pandhi S, Nixon RM, Guyot P, Karabis A, Moore RA.
    Arthritis Res Ther; 2015 Mar 19; 17(1):66. PubMed ID: 25879879
    [Abstract] [Full Text] [Related]

  • 10. [Comparative evaluation of the safety and efficacy of etoricoxib and diclofenac on the upper gastrointestinal tract in patients with osteoarthrosis and rheumatoid arthritis (the multinational etoricoxib and diclofenac arthritis long-term (MEDAL) study program)].
    Alekseeva LI.
    Ter Arkh; 2010 Mar 19; 82(8):57-62. PubMed ID: 20873248
    [Abstract] [Full Text] [Related]

  • 11. Cardiovascular safety of lumiracoxib: a meta-analysis of all randomized controlled trials > or =1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis.
    Matchaba P, Gitton X, Krammer G, Ehrsam E, Sloan VS, Olson M, Mellein B, Hoexter G, Orloff J, Garaud JJ.
    Clin Ther; 2005 Aug 19; 27(8):1196-214. PubMed ID: 16199245
    [Abstract] [Full Text] [Related]

  • 12. Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) study program: cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis.
    Cannon CP, Curtis SP, Bolognese JA, Laine L, MEDAL Steering Committee.
    Am Heart J; 2006 Aug 19; 152(2):237-45. PubMed ID: 16875903
    [Abstract] [Full Text] [Related]

  • 13. [3 questions about gastrointestinal risk. Are coxibs here clearly better than NSAID?]].
    Krüger K.
    MMW Fortschr Med; 2006 Nov 30; 148(48):12. PubMed ID: 17615761
    [No Abstract] [Full Text] [Related]

  • 14. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events.
    Hunt RH, Harper S, Watson DJ, Yu C, Quan H, Lee M, Evans JK, Oxenius B.
    Am J Gastroenterol; 2003 Aug 30; 98(8):1725-33. PubMed ID: 12907325
    [Abstract] [Full Text] [Related]

  • 15. Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).
    Krueger K, Lino L, Dore R, Radominski S, Zhang Y, Kaur A, Simpson R, Curtis S.
    Ann Rheum Dis; 2008 Mar 30; 67(3):315-22. PubMed ID: 17965424
    [Abstract] [Full Text] [Related]

  • 16. Clinical use and pharmacological properties of selective COX-2 inhibitors.
    Shi S, Klotz U.
    Eur J Clin Pharmacol; 2008 Mar 30; 64(3):233-52. PubMed ID: 17999057
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies.
    Bingham CO, Sebba AI, Rubin BR, Ruoff GE, Kremer J, Bird S, Smugar SS, Fitzgerald BJ, O'Brien K, Tershakovec AM.
    Rheumatology (Oxford); 2007 Mar 30; 46(3):496-507. PubMed ID: 16936327
    [Abstract] [Full Text] [Related]

  • 18. A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis.
    Matsumoto AK, Melian A, Mandel DR, McIlwain HH, Borenstein D, Zhao PL, Lines CR, Gertz BJ, Curtis S, Etoricoxib Rheumatoid Arthritis Study Group.
    J Rheumatol; 2002 Aug 30; 29(8):1623-30. PubMed ID: 12180720
    [Abstract] [Full Text] [Related]

  • 19. [Coronary risks with NSAID and coxibs. The end of hysteria].
    Einecke D.
    MMW Fortschr Med; 2006 Nov 30; 148(48):10, 12. PubMed ID: 17615760
    [No Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of etoricoxib compared with NSAIDs in acute gout: a systematic review and a meta-analysis.
    Zhang S, Zhang Y, Liu P, Zhang W, Ma JL, Wang J.
    Clin Rheumatol; 2016 Jan 30; 35(1):151-8. PubMed ID: 26099603
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.